medigraphic.com
ISSN 0016-3813 (Print)

2012, Number 4

<< Back Next >>

Gac Med Mex 2012; 148 (4)

Metaplastic breast cancer: Clinical factors

Barquet MSA, Villarreal CSP, Cantú LDF, Rangel NHA, Lozano GRA, López NRA, Gómez PD

Language: Spanish
References: 28
Page: 339-348
PDF size: 96.81 Kb.


ABSTRACT

Background: metaplastic breast carcinoma (MBC) is uncommon, characterized by a heterogeneous mixture of histologic characteristics. Objective: evaluate clinical and pathological characteristics in a population of patients with MBC in a reference center. Materials and methods: retrospective analysis of cases diagnosed with MBC at INCAN database from 2005-2011 was performed. Univariate assessment of clinical variables and their impact on disease free survival (DFS) and overall survival (OS) were evaluated. Results: the records of 20 patients were identified. Median age was 49.5 (range: 33-75). Clinical stages at diagnosis were 6 I-II (30%) and 14 III-IV (70%). Three year OS was 52.1%. Patients ‹ 40 years had an OS of 32.8 months vs. ≥ 40 years of 17.8 (p = 0.097). OS in stage I-II was 13.5 months vs. 23.3 months in III-IV (p = 0.99). Those who received neoadjuvant therapy had an OS of 26.57 vs. 14.36 in those who did not (p = 0.54). Those who received adjuvant therapy had an OS of 31.2 months vs. 11.15 in those who did not (p = 0.036). Conclusions: MBC has bad prognosis, nevertheless, age ‹ 40 years and hormone receptor positivity, as well as adjuvant treatment seems to be factors that have an influence OS.


REFERENCES

  1. GLOBOCAN 2008. Cancer Incidence and Mortality Worldwide in 2008 [on-line]. [Ingresado el 10 de enero de 2011]. Tomado de http://globocan. iarc.fr/factsheets/populations/factsheet.asp?uno=484.

  2. Harvey JA. Unusual breast cancers: useful clues to expanding the differential diagnosis. Radiology. 2007;242:683-894.

  3. Tseng WH, Martínez SR. Metaplastic breast cancer: to radiate or not to radiate? Ann Surg Oncol. 2011;18:94-103.

  4. Gibson GR, Qian D, Ku JK, Lai LL. Metaplastic breast cancer: clinical features and outcomes. Am Surg. 2005;71:725-30.

  5. Yamaguchi R, Horii R, Maeda I, et al. Clinicopathologic study of 53 metaplastic breast carcinomas: their elements and prognostic implications. Hum Pathol. 2010;41:679-85.

  6. Park JM, Han BK, Moon WK, Choe YH, Ahn SH, Gong G. Metaplastic carcinoma of the breast: mammographic and sonographic findings. J Clin Ultrasound. 2000;28:179-86.

  7. Luini A, Aguilar M, Gatti G, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2007;101:349-53.

  8. Catroppo JF, Lara JF. Metastatic metaplastic carcinoma of the breast (MCB): an uncharacteristic pattern of presentation with clinicopathologic correlation. Diagn Cytopathol. 2001;25:285-91.

  9. Beatty JD, Atwood M, Tickman R, Reiner M. Metaplastic breast cancer: clinical significance. Am J Surg. 2006;191:657-64.

  10. Tse GM, Tan PH, Putti TC, Lui PC, Chaiwun B, Law BK. Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol. 2006;59:1079-83.

  11. Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14:166-73.

  12. Dave G, Cosmatos H, Do T, Lodin K, Varshney D. Metaplastic carcinoma of the breast: a retrospective review. Int J Radiat Oncol Biol Phys. 2006;64:771-5.

  13. Tavassoli FA, Devilee P, eds. World Health Organization classification of tumours: pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.

  14. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrixproducing carcinoma. Hum Pathol. 1989;20:628-35.

  15. Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol. 1989;20:732-40.

  16. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer. 1989;64:1490-9.

  17. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer. 1990;65:272-6.

  18. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol. 1990;21:1142-50.

  19. Gilbert JA, Goetz MP, Reynolds CA, et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther. 2008;7:944-51.

  20. Jung SY, Kim HY, Nam BH, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2010;120:627-37.

  21. Okada N, Hasebe T, Iwasaki M, et al. Metaplastic carcinoma of the breast. Hum Pathol. 2010;41:960-70.

  22. Vela-Chávez TA, Ruvalcaba-Limón E, Pérez-Sánchez VM, Geist B, Naehrig J, Fend F. EGFR analysis in metaplastic carcinoma of the breast. Eur J Cancer. 2008;6:86.

  23. Al Sayed AD, El Weshi AN, Tulbah AM, Rahal MM, Ezzat AA. Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors. Acta Oncol. 2006;45:188-95.

  24. Chen IC, Lu YS, Lin CH, Huang CS, Cheng AL. Poor response to systemic chemotherapy in metaplastic carcinoma of breast. EJC. 2009;7:289.

  25. Hennessy BT, Giordano S, Broglio K, et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006;17:605-13.

  26. Chao TC, Wong CS, Chen MF. Metaplastic carcinoma of the breast. J Surg Oncol. 1999;71:220-5.

  27. Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999;10:413-9.

  28. Lim KH, Oh DY, Chie EK, et al. Metaplastic breast carcinoma: clinicopathologic features and prognosis value of triple negativity. Jpn J Clin Oncol. 2010;40:112-8




2020     |     www.medigraphic.com